298 related articles for article (PubMed ID: 28347525)
1. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.
Tomasello G; Petrelli F; Ghidini M; Pezzica E; Passalacqua R; Steccanella F; Turati L; Sgroi G; Barni S
Eur J Surg Oncol; 2017 Sep; 43(9):1607-1616. PubMed ID: 28347525
[TBL] [Abstract][Full Text] [Related]
2. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
[TBL] [Abstract][Full Text] [Related]
3. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
4. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
[TBL] [Abstract][Full Text] [Related]
5. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
6. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M
Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892
[TBL] [Abstract][Full Text] [Related]
8. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
Ajani JA; Mansfield PF; Crane CH; Wu TT; Lunagomez S; Lynch PM; Janjan N; Feig B; Faust J; Yao JC; Nivers R; Morris J; Pisters PW
J Clin Oncol; 2005 Feb; 23(6):1237-44. PubMed ID: 15718321
[TBL] [Abstract][Full Text] [Related]
10. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
[TBL] [Abstract][Full Text] [Related]
11. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
12. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
[TBL] [Abstract][Full Text] [Related]
13. Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis.
Tie H; He F; Shen J; Zhang B; Ye M; Chen B; Wu Q
Dis Esophagus; 2018 Jan; 31(1):1-9. PubMed ID: 29087451
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the red cell distribution width in esophageal cancer patients: A systematic review and meta-analysis.
Xu WY; Yang XB; Wang WQ; Bai Y; Long JY; Lin JZ; Xiong JP; Zheng YC; He XD; Zhao HT; Sang XT
World J Gastroenterol; 2018 May; 24(19):2120-2129. PubMed ID: 29785080
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
[TBL] [Abstract][Full Text] [Related]
16. Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer.
Muijs C; Smit J; Karrenbeld A; Beukema J; Mul V; van Dam G; Hospers G; Kluin P; Langendijk J; Plukker J
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):845-52. PubMed ID: 24411191
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Value of a Pathologic Complete Response After Neoadjuvant Therapy for Digestive Cancer: Systematic Review and Meta-Analysis of 21 Studies.
Wan T; Zhang XF; Liang C; Liao CW; Li JY; Zhou YM
Ann Surg Oncol; 2019 May; 26(5):1412-1420. PubMed ID: 30805807
[TBL] [Abstract][Full Text] [Related]
19. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
20. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
